Health & Research Goals
AHK-Cu (Copper Tripeptide-3 / Alanyl-Histidyl-Lysine Copper)
AHK-Cu (Tripéptido de Cobre-3 / Alanil-Histidil-Lisina Cobre)
AHK-Cu is a synthetic copper-chelated tripeptide (Ala-His-Lys) engineered specifically to target dermal papilla cells and skin fib…
Primary Description
AHK-Cu is a synthetic copper-chelated tripeptide (Ala-His-Lys) engineered specifically to target dermal papilla cells and skin fibroblasts. Unlike its close relative GHK-Cu (which occurs naturally in human plasma), AHK-Cu was deliberately designed for superior hair follicle activity — stimulating VEGF production, suppressing TGF-β1, and elevating the Bcl-2/Bax ratio to extend the anagen (active growth) phase. Applied topically in serum formulations, it has gained a strong following in both the hair loss community and the skin-focused biohacker market as a complement to or replacement for GHK-Cu.
Key Benefits
- Hair growth
- Skin rejuvenation
- Wound healing
Relatively stable in properly formulated vehicles. Copper ion is sensitive to pH extremes and oxidizing agents. Avoid combining with high-dose ascorbic acid in the same formulation (vitamin C can destabilize copper peptide complexes). Store in dark glass at 2–8°C. Use formulations within 30 days of opening. Liposomal encapsulation significantly improves stability and dermal penetration.
Demonstrated Effects
- Stimulates hair follicle elongation — active at concentrations as low as 10⁻¹² M in ex vivo studies
- Extends anagen (growth) phase of the hair cycle via dermal papilla cell activation
- Increases VEGF production for improved scalp blood flow and follicle nutrition
- Suppresses TGF-β1 — a key driver of hair follicle miniaturization in androgenic alopecia
- Elevates Bcl-2/Bax ratio to reduce apoptosis in follicle-supporting cells
- Stimulates fibroblast proliferation and collagen/elastin synthesis for skin rejuvenation
- Enhances SOD (superoxide dismutase) activity — reduces oxidative stress in scalp tissue
- Delivers bioavailable copper for lysyl oxidase activity — critical for collagen and elastin cross-linking
Proposed Mechanisms of Action
1. VEGF Upregulation and Angiogenesis
AHK-Cu significantly increases vascular endothelial growth factor (VEGF) production in dermal papilla cells. VEGF promotes the formation of new blood vessels, improving nutrient and oxygen delivery to hair follicles.
Improved scalp vascularization directly supports follicle health and is one mechanism by which AHK-Cu extends the anagen phase.
2. TGF-β1 Suppression
TGF-β1 (Transforming Growth Factor Beta-1) drives follicle miniaturization in androgenic alopecia and promotes hair cycle termination (catagen). AHK-Cu reduces TGF-β1 secretion in fibroblasts, counteracting a key pathological driver of hair loss.
Mechanistically relevant to androgenic alopecia — addresses DHT-induced follicle miniaturization at the TGF-β pathway level.
3. Anti-Apoptotic Signaling (Bcl-2/Bax)
AHK-Cu elevates the ratio of Bcl-2 (anti-apoptotic) to Bax (pro-apoptotic) in follicle-supporting cells. Higher Bcl-2/Bax ratios mean dermal papilla cells survive longer, supporting prolonged anagen phase.
Extends the active growth phase of individual hair follicles, directly contributing to hair density over time.
4. Copper Delivery and Enzymatic Cofactor Activity
Copper is a critical cofactor for lysyl oxidase (collagen/elastin cross-linking), tyrosinase (melanin synthesis), and superoxide dismutase (antioxidant defense). AHK-Cu delivers bioavailable copper directly to target tissues without the oxidative risk of free copper ions.
Supports structural integrity of the dermal matrix and reduces oxidative stress in the scalp microenvironment.
Research Evidence & Clinical Data
Investigated Applications
Hair Loss (Androgenic and Non-Androgenic Alopecia)
Anecdotal: ModerateThe primary application driving community interest. Users exploring peptide-based approaches to hair loss report AHK-Cu as showing more hair-specific activity than GHK-Cu, with some reporting reduced shedding and new growth in problem areas within 8–16 weeks. Results are described as modest and cumulative — not a dramatic single-compound solution, but a meaningful contributor in multi-compound protocols.
Preclinical basis: Ex vivo human hair follicle studies: AHK-Cu stimulates follicle elongation at extremely low concentrations (10⁻¹² M). In vitro: VEGF upregulation, TGF-β1 suppression, anti-apoptotic signaling in dermal papilla cells.
Skin Anti-Aging and Dermal Regeneration
Anecdotal: ModerateSecondary to hair use but gaining traction for facial skin applications. Users report improved skin firmness, texture, and reduced fine line appearance with consistent use. The fibroblast stimulation and copper-dependent collagen cross-linking activity make it a mechanistically sound anti-aging ingredient.
Preclinical basis: In vitro: increases fibroblast proliferation, collagen I and III synthesis, elastin production, and glycosaminoglycan deposition. Copper cofactor for lysyl oxidase — essential for structural cross-linking of dermal matrix.
Wound Healing and Scalp Recovery
Anecdotal: EmergingPost-microneedling and post-hair-transplant recovery is a niche but growing use case. The wound-healing and angiogenic properties of AHK-Cu are seen as beneficial in the recovery phase after scalp procedures.
Preclinical basis: Copper peptides broadly promote angiogenesis (VEGF pathway), fibroblast recruitment, and extracellular matrix remodeling — well-established mechanisms in wound healing research.
Safety Profile
Common Side Effects
- Mild skin/scalp irritation or redness, particularly at high concentrations or on sensitive skin
- Transient increased shedding in the first 2–4 weeks (telogen effluvium-like effect as follicles shift to anagen)
- 'Copper uglies' phenomenon reported in some users — paradoxical skin texture changes possibly related to MMP upregulation at excessive concentrations
- Potential for contact dermatitis in individuals with metal sensitivities
- Formulation-dependent irritation (carrier vehicle ingredients may be the primary cause)
- Minimal
Contraindications
- Wilson's disease or other copper metabolism disorders — absolute contraindication
- Active scalp infections or open wounds at application site
- Known hypersensitivity to copper or copper peptide formulations
- Avoid during pregnancy unless verified safe by a healthcare provider — limited safety data
- Copper sensitivity
Pre-Use Screening Checklist
Wilson's disease and other copper dysregulation conditions are absolute contraindications to any copper peptide use.
Active scalp infection, psoriasis plaques, or open wounds should be resolved before starting topical peptide application.
Ensure no formulation conflicts with existing topicals (particularly high-dose vitamin C, retinoids, or other actives applied at the same time).
Legal & Regulatory Status
Not FDA-approved as a drug. Regulated as a cosmetic ingredient in topical formulations (cosmeceutical status). INCI name: Copper Tripeptide-3. Generally recognized as safe at cosmetic concentrations.
Not specifically listed as a prohibited substance. Topical-only use with minimal systemic absorption — WADA risk is considered negligible.
Available as cosmetic/cosmeceutical ingredient. No COFEPRIS-specific pharmaceutical classification. Widely sold in research and cosmetic serum formulations.
Permitted as a cosmetic ingredient under EU Cosmetics Regulation. Listed under INCI name Copper Tripeptide-3.
Cosmetic use permitted under TGA Therapeutic Goods Act when within cosmetic concentration ranges. ARTG listing not required at cosmetic concentrations.
Research Protocols
Dosing Protocols
Hair growth and scalp health — standard topical protocol
Topical — scalp serumSkin anti-aging facial application
Topical — facial serumMicroneedling enhancement protocol
Topical post-procedureRoutes of Administration
Topical serum (scalp)
Most commonLeave-in serum applied directly to the scalp. Primary route for hair growth applications.
No needles, no reconstitution needed for pre-formulated serums. Part hair and apply drops directly to scalp surface.
Topical serum (facial/body skin)
Specific useApplied as a facial serum for anti-aging and collagen support. Can be used on other body areas with skin concerns.
Layer under moisturizers. Avoid eye contact. Conduct patch test if skin sensitivity is a concern.
Reconstitution Guide
Not required for pre-formulated topical serums. For raw AHK-Cu powder: dissolve in purified water or appropriate cosmetic vehicle (e.g., propylene glycol solution, liposomal base).
Raw powder: weigh target concentration (e.g., 2 g per 100 mL for 2%), dissolve in warm purified water with gentle stirring, then incorporate into serum base at room temperature. Adjust pH to 5.5–6.5 to preserve copper complex stability.
2% formulation: 2 g AHK-Cu powder dissolved in base vehicle to make 100 mL. 5% formulation: 5 g per 100 mL. Commercial ready-made serums typically arrive at target concentration.
Store finished formulation at 2–8°C in a dark glass or opaque container. Use within 30 days. Avoid freezing.
Raw lyophilized AHK-Cu powder: store at 2–8°C away from light and moisture. Stable for 12–24 months under proper conditions.
Evening application preferred — the hair follicle cycle and skin repair processes are most active during sleep. If using alongside minoxidil, apply minoxidil first and wait 10–15 minutes before applying AHK-Cu to avoid formulation interactions and allow initial absorption.
Pharmacokinetics
| Half-Life | Not formally established for topical AHK-Cu. Minimal systemic absorption from topical application limits pharmacokinetic characterization. |
| Absorption | Topical application: skin penetration confirmed in ex vivo studies. Permeation coefficient of 2.43 × 10⁻⁴ cm/h; 136.2 μg/cm² copper permeated through dermatomed skin over 48 hours. 97 μg/cm² retained as a dermal depot — indicating effective local delivery. Molecular weight of ~417 g/mol is below the 500 Da threshold for transdermal penetration. Liposomal encapsulation significantly enhances penetration. |
| Distribution | Following topical application, distributed primarily within the epidermis and upper dermis. Reaches dermal papilla cells in the follicle when combined with penetration enhancers or microneedling. Systemic distribution following topical use is minimal. |
| Metabolism | Copper peptides are degraded by extracellular proteases in the dermis. Copper is released locally and enters normal copper metabolism pathways. Tripeptide component metabolized to constituent amino acids. |
| Molecular Structure | Tripeptide sequence Ala-His-Lys chelated to Cu2+. The histidine imidazole ring provides the primary copper coordination site. MW: ~417 g/mol. CAS: 682809-81-0. Hydrophilic character with moderate lipophilicity, enabling reasonable membrane permeation. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Scalp and skin responseWatch for excessive irritation, redness, or unexpected skin texture changes. If 'copper uglies' phenomenon (accelerated wrinkling or textural changes) appears, discontinue immediately.Check: Weekly for first month
- Hair shedding and growth progressInitial shedding increase (weeks 1–4) is normal and indicates follicle cycling. New growth (vellus to terminal hairs) should be visible by weeks 8–16 with consistent use.Check: Monthly
Critical Warning Signs
- Severe scalp irritation, chemical burn, or significant redness/swellingDiscontinue use. Wash area thoroughly with mild shampoo and water. Consult a dermatologist if symptoms persist beyond 48 hours.Urgency: Within 24-48 hours
- Paradoxical skin worsening — visible skin aging, unusual texture changes ('copper uglies')Reduce concentration or discontinue. This is theorized to result from MMP overactivation at excessive copper levels. Switch to a lower concentration formulation.Urgency: Within 1 week if persistent
Featured in Stacking Protocols
Community-researched combinations involving this compound
Minoxidil (5% topical)
Copper + Minoxidil ProtocolComplementary hair growth via different mechanisms — vasodilation + follicle-level signaling
Minoxidil dilates scalp blood vessels and opens potassium channels (mechanism not fully elucidated). AHK-Cu works at the cellular level — VEGF upregulation, TGF-β1 suppression, anti-apoptotic signaling. Addressing both vascular supply and follicle-level biology is the rationale for combining them.
Minoxidil applied first (morning or evening), wait 10–15 minutes, then apply AHK-Cu 2–5% serum. Once or twice daily.
GHK-Cu (Copper Tripeptide-1)
Dual Copper Peptide StackComprehensive skin repair + targeted hair follicle activation
GHK-Cu provides broad tissue repair, wound healing, and skin anti-aging effects. AHK-Cu contributes hair follicle-specific activity. Combined formulations target both systemic skin health and localized hair growth support.
Commercial serums combining 5–10% GHK-Cu + 2–5% AHK-Cu applied to scalp daily. Or separate applications at different times of day.
Microneedling (Dermaroller / Dermapen)
Microneedling + Copper Peptide ProtocolDramatically enhance copper peptide dermal penetration and delivery to follicle level
Microneedling creates transient microchannels through the stratum corneum — bypassing the primary barrier to peptide penetration. AHK-Cu applied during or immediately after achieves far greater follicle-level delivery than topical application alone.
Microneedling at 0.5–1.0 mm, once weekly. Apply AHK-Cu 2–5% serum immediately post-procedure. Resume daily topical application the following day.
Finasteride / Dutasteride (5-alpha reductase inhibitors)
Finasteride / Dutasteride (5-alpha reductase inhibitors) Synergy StackDHT suppression + follicle-level support
5-ARIs reduce DHT-driven follicle miniaturization. AHK-Cu counteracts TGF-β1 (downstream of DHT signaling) and supports the follicle environment independent of hormonal DHT levels. Multi-level approach to androgenic alopecia.
Finasteride/dutasteride per physician guidance; AHK-Cu 2–5% topical daily.